Massot-Cladera Malén, Rigo-Adrover María Del Mar, Herrero Laura, Franch Àngels, Castell Margarida, Vulevic Jelena, Pérez-Cano Francisco J, Lagunas María J Rodríguez
Departament de Bioquímica i Fisiologia, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Av. Joan XXIII 27-31, 08028 Barcelona, Spain.
Institut de Recerca en Nutrició i Seguretat Alimentària (INSA), C/Prat de la Riba 171, 08921 Santa Coloma de Gramanet, Spain.
Cells. 2022 May 18;11(10):1669. doi: 10.3390/cells11101669.
The leading cause of gastroenteritis among young children worldwide is the Group A rotaviruses (RV), which produce a wide range of symptoms, from a limited diarrhea to severe dehydration and even death. After an RV infection, immunity is not complete and less severe re-infections usually occur. These infections could be ameliorated by nutritional interventions with bioactive compounds, such as prebiotics. The aim of this research was to study the impact of a particular galactooligosaccharide (B-GOS) on the RV symptomatology and immune response during two consecutive infections. Lewis neonatal rats were inoculated with SA11 (first RV infection) on day 6 of life and with EDIM (second RV infection) on day 17 of life. B-GOS group was administered by oral gavage with a daily dose of B-GOS between days three to nine of life. Clinical and immunological variables were assessed during both infective processes. In the first infection, after the prebiotic intervention with B-GOS, a lower incidence, duration, and overall severity of the diarrhea (p < 0.05) was observed. In addition, it improved another severity indicator, the fecal weight output, during the diarrhea period (p < 0.05). The second RV infection failed in provoking diarrhea in the groups studied. The immune response during first infection with SA11 was not affected by B-GOS administration and had no impact on second infection, but the prebiotic intervention significantly increased IFN-γ and TNF-α intestinal production after the second infection (p < 0.05). In summary, B-GOS supplementation is able to reduce the incidence and severity of the RV-associated diarrhea and to influence the immune response against RV infections.
全球范围内，幼儿肠胃炎的主要病因是A组轮状病毒（RV），它会引发一系列症状，从轻微腹泻到严重脱水甚至死亡。感染RV后，免疫并不完全，通常会发生不太严重的再次感染。这些感染可以通过使用生物活性化合物（如益生元）进行营养干预来改善。本研究的目的是研究一种特定的低聚半乳糖（B-GOS）在连续两次感染期间对RV症状和免疫反应的影响。在出生第6天给新生Lewis大鼠接种SA11（第一次RV感染），在出生第17天接种EDIM（第二次RV感染）。在出生后第3天至第9天，通过口服灌胃给B-GOS组每日服用一剂B-GOS。在两个感染过程中评估临床和免疫变量。在第一次感染中，用B-GOS进行益生元干预后，观察到腹泻的发生率、持续时间和总体严重程度较低（p<0.05）。此外，它还改善了腹泻期间的另一个严重程度指标——粪便重量输出（p<0.05）。在研究的组中，第二次RV感染未引发腹泻。第一次感染SA11期间的免疫反应不受B-GOS给药的影响，对第二次感染也没有影响，但益生元干预在第二次感染后显著增加了肠道IFN-γ和TNF-α的产生（p<0.05）。总之，补充B-GOS能够降低RV相关腹泻的发生率和严重程度，并影响针对RV感染的免疫反应。
